Drugs / SCB-2023B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06567457 | Oct 2023 → Sep 2024 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCB-2023B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06567457 ↗ |
| Modality | Vaccine | “SCB-2023B vaccine” NCT06567457 ↗ |